+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Durability of HBeAG seroconversion in chronic hepatitis B patients after lamivudine A-interferon or lamivudine A- interferon combination therapy



Durability of HBeAG seroconversion in chronic hepatitis B patients after lamivudine A-interferon or lamivudine A- interferon combination therapy



Journal of Hepatology 34(Suppl. 1): 155




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 034772011

Download citation: RISBibTeXText

DOI: 10.1016/s0168-8278(01)81440-9


Related references

Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients. American Journal of Gastroenterology 100(11): 2463-2471, 2005

Lamivudine/pegylated interferon alfa-2b sequential combination therapy compared with lamivudine monotherapy in HBeAg-negative chronic hepatitis B. Journal of Gastroenterology and Hepatology 22(10): 1582-1588, 2007

Comparison of lamivudine monotherapy with lamivudine plus interferon alpha combination in patients with HBeAg positive chronic hepatitis B. Journal of Hepatology 34(Suppl. 1): 177-178, 2001

A reduction study of seroconversion of HBsAg in chronic hepatitis B patients with HBeAg positive by combination treatment with interferon and lamivudine. Zhonghua Gan Zang Bing Za Zhi 17(6): 472-473, 2010

Viral kinetics during 16 weeks of interferon and lamivudine monotheraphy versus interferon-lamivudine combination therapy in chronic hepatitis B patients. Hepatology 32(4 Pt 2): 379A, 2000

Lamivudine monotherapy and interferon plus lamivudine combination therapy in anti-HBe positive patients with chronic hepatitis B who have failed previously interferon treatment. Journal of Hepatology 34(Suppl. 1): 167, 2001

Long term efficacy of interferon and Thymosin combination in comparison to lamivudine+interferon and interferon monotherapy in patients with HBeAg negative chronic hepatitis B. Journal of Hepatology 38(Suppl. 2): 169, 2003

Lamivudine monotherapy and lamivudine plus interferon alpha combination therapy in HBeAg negative chronic hepatitis B not responding to previous interferon alpha monotherapy. Acta Gastro-Enterologica Belgica 70(1): 20-24, 2007

Higher efficacy of sequential therapy of lamivudine and interferon compared to lamivudine monotherapy in HBeAg positive, chronic hepatitis B patients. Gastroenterology 123(1 Suppl.): 69, 2002

Lamivudine vs lamivudine and interferon combination treatment of HBeAg(-) chronic hepatitis B. Journal of Viral Hepatitis 12(3): 262-268, 2005

Higher efficacy of sequential therapy of lamivudine and interferon-A vs lamivudine monotherapy in patients with HBeAg positive chronic hepatitis B A prospective randomized controlled trial. Journal of Hepatology 40(Suppl 1): 131, 2004

Interferon alpha2a in combination with lamivudine in the treatment of patients with chronic HbeAg hepatitis B non-responders to interferon monotherapy. Journal of Hepatology 36(Suppl. 1): 245, 2002

Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. Journal of Hepatology 38(6): 818-826, 2003

Interferon plus lamivudine therapy for patients with chronic hepatitis B with and without HBeAg who relapsed after interferon treatment. Journal of Hepatology 30(SUPPL 1): 135, 1999

Effectiveness of lamivudine and interferon-alpha combination therapy versus interferon-alpha monotherapy for the treatment of HBeAg-negative chronic hepatitis B patients: a randomized clinical trial. Journal of Microbiology, Immunology, and Infection 38(4): 262-266, 2005